The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4451-4456

  Chikaishi, Yasuhiro ^a   Uramoto, Hidetaka ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

E cadherin; EMT; Fibronectin; Gamma catenin; Lung adenocarcinoma; Vimentin

Indexed keywords

CARBOPLATIN; FIBRONECTIN; GEMCITABINE; PACLITAXEL; PLAKOGLOBIN; UFT; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PATHOLOGY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOEMBRYONIC ANTIGEN; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBRONECTINS; GAMMA CATENIN; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POSTOPERATIVE PERIOD; RECURRENCE; VIMENTIN;

EID: 84855162618     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Smith W and Khuri FR: The care of the lung cancer patient in the 21st century: a new age. Semin Oncol 31: 11-15, 2004. (Pubitemid 38609787)
2. Hanagiri T, Baba T, So T, Yasuda M, Ono K, So T, Uramoto H, Takenoyama M and Yasumoto K: Time trends of surgical outcome in patients with non-small cell lung cancer. J Thorac Oncol 5: 825-829, 2010.
3. Nakagawa M, Uramoto H, Shimokawa H, Onitsuka T, Hanagiri T and Tanaka F: Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung. Exp Ther Med 2: 585-590, 2011.
4. Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K and Hanagiri T: TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer 72: 360-364, 2011.
5. Gu C, Uramoto H. Onitsuka T, Shimokawa H, Iwanami T, Nakagawa M, Oyama T and Tanaka F: Molecular diagnosis of MACCl status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 31: 1141-1145, 2011.
6. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
7. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 30: 2513-2517, 2010.
8. Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4: 1049-1059, 2009.
9. Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K and Yasumoto K: A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. Anticancer Res 30: 4695-4699, 2010.
10. Sugaya M, Uramoto H, Uchiyama A, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Hanagiri T and Yasumoto K: Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. Anticancer Res 30: 3039-3044, 2010.
11. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T and Yasumoto K: Association between lymphangiogenesis-/ micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 70: 320-328, 2010.
12. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 68: 198-203, 2010.
13. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K and Yasumoto K: Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911, 2004. (Pubitemid 39383040)
14. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
15. Lee YC, Wu CT, Chen CS, Hsu HH and Chang YL: The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 123: 502-507, 2002.
16. Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY and Chen M: Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn J Clin Oncol 40: 670-676, 2010.
17. Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H, Takenaka T, Yohena T and Maehara Y: Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer 110: 369-374, 2007. (Pubitemid 47121898)
18. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, Haura E and Chellappan S: Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 124: 36-45, 2009.
19. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM and Haley JD: A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 28: 137-155, 2011.
20. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM and Busund LT: The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small cell lung cancer. Br J Cancer 99: 1476-1483, 2008.
21. Pelletier MP, Edwardes MD, Michel RP, Halwani F and Morin JE: Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 44: 180-188, 2001. (Pubitemid 32538769)